Top segments and regional performance

Last year, the company generated ‪21.16 M‬ AUD, the most of which — ‪14.56 M‬ AUD — came from its top-performing segment, Immunotherapy, compared to ‪170.37 K‬ AUD the previous year. The greatest contribution came from Australia, which accounted for ‪14.56 M‬ AUD last year, with ‪170.37 K‬ AUD the year before.